A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Naïve Patients with Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine the safety and efficacy of Umbralisib (TGR-1202) in individuals with Chronic Lymphocytic Leukemia (CLL)
PRIMARY OBJECTIVE To evaluate the overall response rate (CR + PR) To determine the progression free survival of TGR-1202 (umbralisib) in patients with CLL SECONDARY OBJECTIVES To assess safety of TGR-1202 (umbralisib), tolerability and other efficacy outcome To determine the pharmacokinetics and pharmacodynamics of TGR-1202 (umbralisib)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.